Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Fatima Karzai(National Institutes of Health), William L. Dahut(National Cancer Institute), Akira Yuno(National Institutes of Health), Ryan Dittamore(Epic Sciences (United States)), Paul S. Meltzer(National Cancer Institute), Maria J. Merino(National Institutes of Health), Jennifer L. Marté(National Cancer Institute), Lisa M. Cordes(National Institutes of Health Clinical Center), Jane B. Trepel(National Institutes of Health), Amy Hankin(National Institutes of Health), Seth M. Steinberg(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Marijo Bilušić(National Institutes of Health), Renee N. Donahue(National Institutes of Health), Kathleen Kelly(National Cancer Institute), Jeffrey Schlom(National Cancer Institute), Keith Killian(National Institutes of Health), Venkatesh Krishnasamy(National Institutes of Health), James L. Gulley(National Cancer Institute), David James VanderWeele(Northwestern University), Anna Couvillon(National Institutes of Health), Jung Min Lee(National Institutes of Health), Sunmin Lee(National Institutes of Health), Helen Owens(National Institutes of Health), E. Hitt Nichols(Leidos (United States)), Min-Jung Lee(National Institutes of Health), Michael L. Beshiri(National Cancer Institute)
Journal for ImmunoTherapy of Cancer
December 1, 2018
Cited by 312


Related Papers